Physician

Mark Karides, MD

According to 2025 Medicare claims, Mark Karides, MD (NPI: 1932206307) practices hematology/oncology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ILLINOIS CANCER SPECIALISTS (NPI: 1164483913; TIN: 363980044) and primary practice location at 60631-3745. Karides is affiliated with the THEDACARE ACO (ACO ID: A4988), participating under the MSSP model.

Karides' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 581 traditional Medicare patients, billed 267,071 HCPCS/CPT codes, and received $4,187,059 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,088 prescription claims across 187 beneficiaries totaling $4,081,429 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 120 records totaling $2,807. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,075,702 to $4,081,429. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	638	317,373	$3,123,347
2016	660	276,650	$2,788,481
2017	599	238,003	$2,719,931
2018	613	246,307	$3,177,698
2019	563	255,187	$3,165,089
2020	384	170,836	$1,969,828
2021	507	292,987	$3,042,442
2022	551	295,647	$3,322,319
2023	564	267,557	$3,465,088
2024	581	267,071	$4,187,059

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	789	$1,075,702
2016	156	837	$1,774,094
2017	178	1,029	$2,295,136
2018	197	1,058	$2,545,013
2019	175	978	$3,065,228
2020	155	829	$3,880,279
2021	155	900	$3,442,461
2022	151	727	$2,792,715
2023	161	900	$3,747,730
2024	187	1,088	$4,081,429

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	81	$7,246
2016	N/R	24	$881
2017	N/R	N/R	N/R
2018	N/R	24	$1,074
2019	N/R	67	$6,140
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$226
2023	N/R	107	$16,119
2024	N/R	12	$100

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	136	152	$140
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	326	1,214	$99
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	155	342	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	228	410	$13
96372	Injection of drug or substance under skin or into muscle	106	548	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	44	1,148	$768,070
Venclexta	Venetoclax	48	1,422	$475,847
Lenalidomide	Lenalidomide	29	770	$419,430
Calquence	Acalabrutinib Maleate	24	720	$378,128
Brukinsa	Zanubrutinib	22	660	$325,377

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$100

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	120	$2,807	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Karides, MD?

Tedicare shows public-source Medicare data for Mark Karides, MD (NPI 1932206307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Karides, MD have ACO affiliation data?

Mark Karides, MD is shown with ACO affiliation data for THEDACARE ACO (MSSP, ACO ID A4988).

What billing organization is linked to Mark Karides, MD?

Mark Karides, MD is linked to ILLINOIS CANCER SPECIALISTS (billing NPI 1164483913) in the available physician profile data.

Does Mark Karides, MD have Open Payments data?

Mark Karides, MD has 120 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.